ATC Group: A10AB04 Insulin lispro

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of A10AB04 in the ATC hierarchy

Defined daily dose

The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.

Route
Amount
PAREN - Parenteral
40 [iU]

Active ingredients in A10AB04

Active Ingredient
Description

The primary activity of insulin lispro is the regulation of glucose metabolism.

Related product monographs

Title
Information Source
Document Type
 
FDA, National Drug Code (US)
MPI, US: SPL/PLR
European Medicines Agency (EU)
MPI, EU: SmPC
European Medicines Agency (EU)
MPI, EU: SmPC

Medicines in this ATC group

United States (US)

Australia (AU)

Austria (AT)

Brazil (BR)

Canada (CA)

Cyprus (CY)

Ecuador (EC)

Estonia (EE)

Finland (FI)

France (FR)

Hong Kong (HK)

Ireland (IE)

Japan (JP)

Lithuania (LT)

Netherlands (NL)

New Zealand (NZ)

Poland (PL)

Romania (RO)

Singapore (SG)

South Africa (ZA)

Spain (ES)

Turkey (TR)

United Kingdom (UK)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.